Continuous infusions of meropenem in ambulatory care: clinical efficacy, safety and stability.

<h4>Objectives</h4>Concerns regarding the clinical impact of meropenem instability in continuous infusion (CI) devices may contribute to inconsistent uptake of this method of administration across outpatient parenteral antimicrobial therapy (OPAT) services.<h4>Methods</h4>We...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Laurens Manning, Cameron Wright, Paul R Ingram, Timothy J Whitmore, Christopher H Heath, Ingrid Manson, Madhu Page-Sharp, Sam Salman, John Dyer, Timothy M E Davis
Formato:	article
Lenguaje:	EN
Publicado:	Public Library of Science (PLoS) 2014
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/a1e9b227dc8340c481db27fb08055074
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:a1e9b227dc8340c481db27fb08055074
record_format	dspace
spelling	oai:doaj.org-article:a1e9b227dc8340c481db27fb080550742021-11-25T06:08:38ZContinuous infusions of meropenem in ambulatory care: clinical efficacy, safety and stability.1932-620310.1371/journal.pone.0102023https://doaj.org/article/a1e9b227dc8340c481db27fb080550742014-01-01T00:00:00Zhttps://www.ncbi.nlm.nih.gov/pmc/articles/pmid/25019523/?tool=EBIhttps://doaj.org/toc/1932-6203<h4>Objectives</h4>Concerns regarding the clinical impact of meropenem instability in continuous infusion (CI) devices may contribute to inconsistent uptake of this method of administration across outpatient parenteral antimicrobial therapy (OPAT) services.<h4>Methods</h4>We retrospectively reviewed the clinical efficacy and safety of CIs of meropenem in two Australian tertiary hospitals and assessed its stability under simulated OPAT conditions including in elastomeric infusion devices containing 1% (2.4 g) or 2% (4.8 g) concentrations at either 'room temperature' or 'cooled' conditions. Infusate aliquots were assayed at different time-points over 24 hours.<h4>Results</h4>Forty-one (82%) of 50 patients had clinical improvement or were cured. Adverse patient outcomes including hemato-, hepato- and nephrotoxicity were infrequent. Cooled infusers with 1% meropenem had a mean 24-hour recovery of 90.3%. Recoveries of 1% and 2% meropenem at room temperature and 2% under cooled conditions were 88%, 83% and 87%, respectively. Patients receiving 1% meropenem are likely to receive >95% of the maximum deliverable dose (MDD) over a 24-hour period whilst patients receiving 2% meropenem should receive 93% and 87% of the MDD under cooled and room temperature conditions, respectively.<h4>Conclusions</h4>Meropenem infusers are likely to deliver ∼95% MDD and maintain effective plasma concentrations throughout the dosing period. These data reflect our local favourable clinical experience with meropenem CIs.Laurens ManningCameron WrightPaul R IngramTimothy J WhitmoreChristopher H HeathIngrid MansonMadhu Page-SharpSam SalmanJohn DyerTimothy M E DavisPublic Library of Science (PLoS)articleMedicineRScienceQENPLoS ONE, Vol 9, Iss 7, p e102023 (2014)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Laurens Manning Cameron Wright Paul R Ingram Timothy J Whitmore Christopher H Heath Ingrid Manson Madhu Page-Sharp Sam Salman John Dyer Timothy M E Davis Continuous infusions of meropenem in ambulatory care: clinical efficacy, safety and stability.
description	<h4>Objectives</h4>Concerns regarding the clinical impact of meropenem instability in continuous infusion (CI) devices may contribute to inconsistent uptake of this method of administration across outpatient parenteral antimicrobial therapy (OPAT) services.<h4>Methods</h4>We retrospectively reviewed the clinical efficacy and safety of CIs of meropenem in two Australian tertiary hospitals and assessed its stability under simulated OPAT conditions including in elastomeric infusion devices containing 1% (2.4 g) or 2% (4.8 g) concentrations at either 'room temperature' or 'cooled' conditions. Infusate aliquots were assayed at different time-points over 24 hours.<h4>Results</h4>Forty-one (82%) of 50 patients had clinical improvement or were cured. Adverse patient outcomes including hemato-, hepato- and nephrotoxicity were infrequent. Cooled infusers with 1% meropenem had a mean 24-hour recovery of 90.3%. Recoveries of 1% and 2% meropenem at room temperature and 2% under cooled conditions were 88%, 83% and 87%, respectively. Patients receiving 1% meropenem are likely to receive >95% of the maximum deliverable dose (MDD) over a 24-hour period whilst patients receiving 2% meropenem should receive 93% and 87% of the MDD under cooled and room temperature conditions, respectively.<h4>Conclusions</h4>Meropenem infusers are likely to deliver ∼95% MDD and maintain effective plasma concentrations throughout the dosing period. These data reflect our local favourable clinical experience with meropenem CIs.
format	article
author	Laurens Manning Cameron Wright Paul R Ingram Timothy J Whitmore Christopher H Heath Ingrid Manson Madhu Page-Sharp Sam Salman John Dyer Timothy M E Davis
author_facet	Laurens Manning Cameron Wright Paul R Ingram Timothy J Whitmore Christopher H Heath Ingrid Manson Madhu Page-Sharp Sam Salman John Dyer Timothy M E Davis
author_sort	Laurens Manning
title	Continuous infusions of meropenem in ambulatory care: clinical efficacy, safety and stability.
title_short	Continuous infusions of meropenem in ambulatory care: clinical efficacy, safety and stability.
title_full	Continuous infusions of meropenem in ambulatory care: clinical efficacy, safety and stability.
title_fullStr	Continuous infusions of meropenem in ambulatory care: clinical efficacy, safety and stability.
title_full_unstemmed	Continuous infusions of meropenem in ambulatory care: clinical efficacy, safety and stability.
title_sort	continuous infusions of meropenem in ambulatory care: clinical efficacy, safety and stability.
publisher	Public Library of Science (PLoS)
publishDate	2014
url	https://doaj.org/article/a1e9b227dc8340c481db27fb08055074
work_keys_str_mv	AT laurensmanning continuousinfusionsofmeropeneminambulatorycareclinicalefficacysafetyandstability AT cameronwright continuousinfusionsofmeropeneminambulatorycareclinicalefficacysafetyandstability AT paulringram continuousinfusionsofmeropeneminambulatorycareclinicalefficacysafetyandstability AT timothyjwhitmore continuousinfusionsofmeropeneminambulatorycareclinicalefficacysafetyandstability AT christopherhheath continuousinfusionsofmeropeneminambulatorycareclinicalefficacysafetyandstability AT ingridmanson continuousinfusionsofmeropeneminambulatorycareclinicalefficacysafetyandstability AT madhupagesharp continuousinfusionsofmeropeneminambulatorycareclinicalefficacysafetyandstability AT samsalman continuousinfusionsofmeropeneminambulatorycareclinicalefficacysafetyandstability AT johndyer continuousinfusionsofmeropeneminambulatorycareclinicalefficacysafetyandstability AT timothymedavis continuousinfusionsofmeropeneminambulatorycareclinicalefficacysafetyandstability
_version_	1718414120847409152

Continuous infusions of meropenem in ambulatory care: clinical efficacy, safety and stability.

Ejemplares similares